

## Appendix 3Y

### Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Anatara Lifesciences Limited</b>
<b>ABN</b>	<b>41 145 239 872</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Dr David Brookes
<b>Date of last notice</b>	24 December 2024

#### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct & Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	(a) Tarandi 1996 Pty Ltd <Dr DL Brookes Superfund> ( <b>Tarandi</b> ) (b) Dr David and Ms Elisabeth Brookes <Dahlbrook Family Trust> ( <b>Dahlbrook Family Trust</b> ) (c) Dr David and Ms Elisabeth <Dr DL Brookes Personal Superfund> ( <b>Brookes Superfund</b> )  Dr Brookes is within a class of beneficiaries of the Tarandi, Dahlbrook Family Trust and Brookes Superfund.
	26 November 2025

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>No. of securities held prior to change</b>	<p><b>Direct</b></p> <p>(a) 1,240,000 Ordinary Shares  (b) 175,000 Options exercisable at \$0.07 each and expiring on 11.12.2025  (c) 1,500,000 Options exercisable at \$0.10 each and expiring on 9.7.2028.</p> <p><b>Indirect</b></p> <p><u>Tarandi</u>  5,290,002 Ordinary Shares;</p> <p><u>Dahlbrook Family Trust</u>  (a) 1,000,000 Options exercisable at \$0.10 each and expiring 9.7.2028;  (b) 285,714 Options exercisable at \$0.07 each and expiring 11.12.2025.</p> <p><u>Brookes Superfund</u>  471,429 Options exercisable at \$0.07 each and expiring 11.12.2025.</p>
<b>Class</b>	Ordinary Shares and Options
<b>Number acquired</b>	<p>(a) 1,666,667 Ordinary Shares by Tarandi;  (b) 1,666,667 Ordinary Shares by Dahlbrook Family Trust.</p>
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$40,000

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held after change</b>	<p><b>Direct</b></p> <p>(a) 1,240,000 Ordinary Shares</p> <p>(b) 175,000 Options exercisable at \$0.07 each and expiring on 11.12.2025</p> <p>(c) 1,500,000 Options exercisable at \$0.10 each and expiring on 9.7.2028.</p> <p><b>Indirect</b></p> <p><u>Tarandi</u></p> <p>(a) 6,956,669 Ordinary Shares;</p> <p><u>Dahlbrook Family Trust</u></p> <p>(a) 1,666,667 Ordinary Shares;</p> <p>(b) 1,000,000 Options exercisable at \$0.10 each and expiring 9 July 2028;</p> <p>(c) 285,714 Options exercisable at \$0.07 each and expiring 11 December 2025</p> <p><u>Brookes Superfund</u></p> <p>471,429 Options exercisable at \$0.07 each and expiring 11 December 2025</p>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Tranche 2 Placement Shares as approved at the Company's AGM on 20 November 2025

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Nil
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

---

<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

#### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>Anatara Lifesciences Limited</b>
<b>ABN</b>	<b>41 145 239 872</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Dirk van Dissel
<b>Date of last notice</b>	29 September 2025

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Candour Asset Management Pty Ltd, of which Mr van Dissel is a Director and Shareholder ( <b>Candour Asset</b> )  Candour Advisory Pty Ltd, of which Mr van Dissel is a Director and Shareholder ( <b>Candour Advisory</b> )
<b>Date of change</b>	26 November 2025
<b>No. of securities held prior to change</b>	<b>Candour Asset</b> (a) 2,727,363 Ordinary Shares (b) 850,001 Unlisted Options expiring on 11.12.2025 and exercisable at \$0.07 each  <b>Candour Advisory</b> 1,500,000 Unlisted Options expiring on 11.12.2025 and exercisable at \$0.07 each
<b>Class</b>	Ordinary Shares and Options
<b>Number acquired</b>	3,333,333 Ordinary Shares by Candour Asset

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$40,000
<b>No. of securities held after change</b>	<b>Candour Asset</b> (a) 6,060,696 Ordinary Shares (b) 850,001 Unlisted Options expiring on 11.12.2025 and exercisable at \$0.07 each  <b>Candour Advisory</b> 1,500,000 Unlisted Options expiring on 11.12.2025 and exercisable at \$0.07 each
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Tranche 2 Placement Shares as approved at the Company's AGM on 20 November 2025

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Nil
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

### Part 3 – <sup>+</sup>Closed period

<sup>+</sup> See chapter 19 for defined terms.

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	N/A
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.